DMD is a fatal disease with no cure. Identifying biomarkers linked to DMD patient survival is vital for understanding disease progression, evaluating treatment effectiveness, and enhancing outcomes for those with this rare disease.

Spinocerebellar ataxia is a neurodegenerative disease, affecting 1 to 5 people per 100,000. The identification of biomarkers can provide key insights into the state and progression of a disease, in addition to patient response to treatments. As such, biomarkers can improve the success rates of drug development, accelerating the availability of new therapeutics.

Alzheimer’s disease (AD) is the most prevalent form of dementia. An estimated 6.5 million Americans aged 65 and older are living with Alzheimer’s dementia, a figure which is projected to soar to around 14 million by 2060. Current treatments only offer temporary symptomatic relief, highlighting the importance of AD research.